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toms, quality of life, effort tolerance, and echocardiographic parameters in patients with idiopathic
dilated cardiomyopathy presenting with New York Heart Association (NYHA) class III or IV heart
failure (HF) symptoms.
Methods: We screened 167 patients hospitalized for NYHA class III or IV chronic HF symptoms
and left ventricular (LV) ejection fraction <40%. Of these, 53 were randomly assigned to either
guidelines-based medical therapy alone (23 patients, control group) or ivabradine as add-on therapy
(30 patients) for 3 months with about 1 year follow up.
Results: After 3 months’ treatment, adding ivabradine signiﬁcantly reduced the heart rate from 96
to 72 bpm (p< 0.0001 versus control group), with more improvement in echocardiographic LV
dimensions, LV volumes, LV ejection fraction (p= 0.045), NYHA class symptoms (p= 0.004),
exercise tolerance (p= 0.03), and quality of life (p= 0.02). The average number of hospitalizations
for HF over a mean longer-term follow-up of 13.5 months was 1.0 ± 1.4 in the ivabradine group
versus 2.1 ± 1.1 in the control group (p= 0.003). Heart rate reduction was signiﬁcantly correlatedrting enzyme; DCM, dilated
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80 S. Mansour et al.with better exercise tolerance, quality of life, LV ejection fraction, and NYHA class, together with
fewer HF hospitalizations. Multivariate analysis showed heart rate reduction to be a stronger pre-
dictor for better LV ejection fraction (p= 0.024) and decreased hospitalizations than ivabradine
use.
Conclusion: Adding ivabradine to optimal medical treatment in HF patients improved symptoms,
quality of life, effort tolerance, and echocardiographic parameters, and reduced hospitalization.
This beneﬁcial ivabradine effect is probably due to its heart rate–reducing properties.
ª 2011 Egyptian Society of Cardiology. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
The prevalence of chronic heart failure (HF) in the general
population has been estimated to be around 2–3%.1 Dilated
cardiomyopathy (DCM) is the most common cause of HF in
young adults.2 Despite recent advances in the treatment of
HF, it remains a disabling disorder that can severely affect
the patient’s quality of life, and the prognosis remains
poor.3–5 It is therefore crucial to develop novel therapeutic ap-
proaches to the treatment of chronic HF. The recognition of
elevated heart rate as a risk factor for cardiovascular morbid-
ity and mortality6–8 and its association with sudden cardiac
death9–11 has made lowering the heart rate in HF patients
one of the most important therapeutic approaches. Beta-block-
ers are known to improve morbidity and mortality in patients
with DCM.12 However, the use of beta-blockers in advanced
HF patients is limited due to side effects, including negative
inotropic effects and associated hypotension, which could wor-
sen the HF,13,14 slow intra-cardiac conduction, and their effect
on the peripheral vasculature and the airways.
A new class of selective heart rate–reducing agents has been
discovered, the If channel inhibitors, of which ivabradine is the
only currently available member. Ivabradine selectively inhibits
cardiac pacemaker activity, thus allowing heart rate reduction
without affecting myocardial contractility, conduction velocity,
and refractoriness, or arterial blood pressure.15 Ivabradine has
been shown to improve remodeling of extracellular matrix in
animal models of HF.16 Ivabradine has been demonstrated to
have some beneﬁt in coronary artery disease,17 but its role in
HF of non-ischemic origin is not yet established.
The aim of the study described here was to investigate the
effect of ivabradine on clinical and echocardiographic param-
eters in patients with idiopathic DCM presenting in New York
Heart Association (NYHA) classes III or IV.2. Methods
2.1. Patients
Patients suffering from symptomatic HF referred to the
Department of Cardiology of Ain Shams University were
screened and examined for left ventricular (LV) cardiomyopa-
thy. Initial screening for all patients included assessment for
ischemic heart disease by history, perfusion study or angiogra-
phy, routine laboratory test for liver and renal functions, and
speciﬁc investigations for thyrotoxicosis and collagen disease.
The study protocol was approved by the committee of research
and medical ethics of the cardiology department of Ain Shams
University in October 2008, and informed consent was
obtained from all patients.Inclusion criteriawere idiopathicDCMpatientswithNYHA
class III or IV on presentation and ejection <40% by echocar-
diography. Patients were in sinus rhythm with resting heart rate
>70 bpm as measured on 12-lead electrocardiogram (ECG)
performed after at least 5 min rest. Exclusion criteria included
NYHA class I, coronary artery disease, signiﬁcant rheumatic
valvular heart disease, thyrotoxic heart disease, atrial ﬁbrilla-
tion, severe renal impairment with serum creatinine >3 mg/
dL, and severe hepatic impairment with signs of liver cell failure.
2.2. Study design
Prior to randomization, all patients received diuretics according
to symptoms plus spironolactone (at least 25 mg/day), digoxin,
angiotensin converting enzyme (ACE) inhibitor uptitrated to
the maximally tolerated dose, and carvedilol also uptitrated to
the maximally tolerated dose. All patients had to be on stable
treatment for at least 4 weeks before randomization.
A computer-driven randomization programwas used to allo-
cate the remaining patients to receive either optimal medical
treatment for LV systolicHF according to the European Society
of Cardiology guidelines1 (control group), or optimal medical
treatment with ivabradine added on top (ivabradine group)
for 3 months. Ivabradine was slowly uptitrated according to
the following sequence: (i) Half a 5-mg tablet once daily for
1 week; (ii) half a 5-mg tablet twice daily for 1 week; (iii) one
5-mg tablet in the morning and half a 5-mg tablet daily in the
evening for 1 week; (iv) one 5-mg tablet every 12 h for 1 week;
(v) one 7.5-mg tablet in the morning and half a 7.5-mg tablet
in the evening 1 week; and (vi) one 7.5-mg tablet every 12 h. This
uptitration of ivabradine was guided by the patients’ heart rate
in each visit and their tolerance of the preceding dose. The target
dose was not themaximumdose of 15 mg per day, but rather the
dose that slowed the resting heart rate to <70 bpm provided
that the patient tolerated that dosage.
2.3. Assessments
Baseline assessments at randomization included veriﬁcation of
inclusion and exclusion criteria, relevant medical history, phys-
ical examination including blood pressure (systolic and dia-
stolic) recording of concomitant treatments, and assessment
of NYHA class. Echocardiographic assessment was performed
using vivid5 (Vingmed, GE) system in a core echocardio-
graphic laboratory by an operator blinded to the patient’s
clinical data. Images were acquired in left lateral position in
which standard apical four-chamber, two-chamber, paraster-
nal short-axis views were acquired. LV dimensions were
measured by M-mode of short axis, then fraction shortening
and ejection fraction were calculated by Techoliz formula.
LV volumes were measured in apical four-chamber views by
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tracing, and ejection fraction was calculated by modiﬁed
Simpson technique.
Routine laboratory test including complete blood count
and creatinine, sodium, and potassium levels in serum were
performed. Effort tolerance was evaluated using the warm-
up stage of a modiﬁed Bruce protocol, and calculating the
maximum time needed to develop dyspnea or fatigue. The
Minnesota Living With Heart Failure (MLWHF) question-
naire was used to measure the quality of life and how much
HF prevented patients from living as they wanted during the
past month, assessed by 21 questions scored from 0 to 5, where
0 is no, 1 very little and 5 is very much affected.18
During follow-up at 3 months, the occurrence of prespeci-
ﬁed events (deﬁned as deaths and hospitalizations from any
cause) was recorded, as well as NYHA class, and a physical
examination was conducted including heart rate and blood
pressure. Echocardiographic assessment for LV dimensions,
volumes, and function was performed. Samples were obtained
for the same clinical laboratory test, effort tolerance study, and
MLWHF questionnaire was reassessed. The patients were then
followed up over 1 year on treatment to evaluate long-term
outcome.
2.4. Study outcomes
The study outcomes were changes in echocardiographic
parameters and changes in functional capacity as assessed by
NYHA classiﬁcation, MLWHF questionnaire, and effort tol-
erance evaluated using the warm-up stage of modiﬁed Bruce
treadmill protocol.
2.5. Statistical analysis
Continuous variables are presented as means ± standard devi-
ation (SD) and categorical variables as percentages. Statistical
analysis was performed using commercially available software
(STATA, version 9.2, Stata Corp., College Station, Texas).
Paired continuous variables were compared using paired t-test
for normally distributed data or Wilcoxon signed rank sum
test for non-normally distributed data. Independent continu-
ous variables were compared using a two-sample t-test for nor-
mally distributed data, or a Wilcoxon–Mann–Whitney test for
non-normally distributed data. The Pearson correlation coefﬁ-
cient was obtained to examine the linear relationship between
two normally distributed continuous variables. One-way
ANOVA was used to compare the means among more than
two independent groups. Categorical variables were compared
with the use of the Pearson chi-square test or Fisher’s exact
test, as appropriate. P value <0.05 (2 tailed) was considered
statistically signiﬁcant. Power calculations were based on the
difference between the baseline scan at randomization and
the follow-up within-patients ; 24 patients per group gave
80% power to detect a change of 5% in LV ejection fraction.3. Results
3.1. Study population
The study was conducted at Ain Shams University Hospitals
between October 2008 and January 2010. A total of 167patients were screened (n= 167), after which 114 patients were
excluded due to NYHA class I (n= 25 patients), coronary
artery disease (n= 30), signiﬁcant rheumatic valvular heart
disease (n= 12), thyrotoxic heart disease (n= 3), atrial ﬁbril-
lation (n= 6), severe renal impairment (n= 14), or severe
hepatic impairment (n= 10). Four patients died before
randomization and 10 patients were living too far away to
be followed up. Fifty-three were randomly assigned to either
guidelines-based medical therapy alone (23 patients, control
group) or ivabradine as add-on therapy (30 patients).
The mean age of the studied population was 49 ± 13 years
(range 19–75 years) and 60% were male. About 25% were dia-
betic and 17% had hypertension; mean LV ejection fraction
was 31.0 ± 5.9% (range 20–40%). There were no signiﬁcant
differences in baseline characteristics between the two study
groups (Table 1), with the exception of higher heart rate (96
versus 84 bpm, p= 0.002), smaller left atrial diameter (42 ver-
sus 49 mm, p= 0.002), and less mitral regurgitation in the iva-
bradine group.
The two groups were assigned to the same medical therapy
with no signiﬁcant differences in the dosage of HF medications
(Table 1). In spite of starting carvedilol in all patients, only 10
(19%) of them managed to achieve 50% or more of the target
daily dose of 50 mg. The average daily dose of ivabradine in
the intervention group was 11.6 ± 3.4 mg (range 5–15 mg).
A total of 27 patients in the ivabradine group and 23
patients in the control group completed 3 months’ follow-up.
Over the subsequent longer-term follow-up, with a mean of
13.5-months, there were 3 deaths in the ivabradine group,
due to worsening of HF (n= 2) and adult respiratory distress
syndrome (ARDS) complicating H1N1 inﬂuenza infection
(n= 1), and 3 deaths in the control group (all due to worsen-
ing HF).
3.2. Echocardiographic parameters
There was a greater improvement in echocardiographic LV
dimensions, LV end systolic and end diastolic volumes
(Fig. 1) and LV ejection fraction (Table 2) in the ivabradine
group versus control. The M-mode LV ejection fraction im-
proved from 31.7% to 36.8% (p< 0.001) in the ivabradine
group versus 32.3–34.1% (p= 0.22) in the control group. This
improvement in ejection fraction was statistically different
between the two groups (p= 0.04). There was no signiﬁcant
difference in the other echocardiographic parameters (left
atrial size, degree of mitral regurgitation, or pulmonary artery
systolic pressure) over the study follow-up period.
3.3. Clinical heart failure parameters
There was a signiﬁcant reduction in the heart rate (Table 2)
from 96 to 72 bpm with ivabradine (p< 0.0001 versus base-
line), while the control group had a nonsigniﬁcant heart rate
reduction from 84 to 81 bpm (p= 0.13 versus baseline). The
between-group difference in heart rate at 3 months was
signiﬁcant (p< 0.0001). Arterial blood pressure did not
change signiﬁcantly in either group over the 3-month follow-
up period.
The improvements in exercise tolerance and quality of life
were signiﬁcantly greater in the ivabradine group than in the
control group (p= 0.03 and 0.02, respectively). The NYHA
class symptoms improved in both groups after the 3 months’
Table 1 Baseline characteristics of the studied patient groups (at randomization).
Ivabradine group (n= 30) Control group (n= 23) p Value
Demographic characteristics
Age (years) 47 ± 13 52 ± 13 0.15
Sex (male) 18 (60%) 14 (61%) 0.95
Smoking (current) 8 (26%) 3 (13%) 0.22
Hypertension 5 (17%) 4 (17%) 0.94
Diabetes mellitus 8 (26%) 5 (22%) 0.68
Medical history
Serum creatinine (mg/dL) 1.2 ± 0.2 1.3 ± 0.3 0.90
Serum sodium (mEq/L) 136.8 ± 2.4 138.5 ± 3.9 0.13
Serum potassium (mEq/L) 3.8 ± 0.4 4.0 ± 0.17 0.32
Hemoglobin (g/dl) 11.4 ± 1 11.2 ± 1.4 0.66
Clinical parameters
Heart rate (bpm) 96 ± 15 (range 70–120) 84 ± 10 (range 70–104) 0.0016
Systolic blood pressure (mm Hg) 97 ± 15 91 ± 5 0.33
NYHA class 0.073
Class II 7 (22%) 3 (13%)
Class III 22 (73%) 14 (61%)
Class IV 1 (3%) 6 (26%)
Exercise tolerance (min) 5.5 ± 4.4 3.8 ± 2.7 0.16
Quality of life (MLWHF score) 58.8 ± 7.2 60.3 ± 5.5 0.59
Echo parameters
LV end diastolic diameter (mm) 67.0 ± 8.4 68.1 ± 5.7 0.21
LV end systolic diameter (mm) 57.1 ± 8.3 58.3 ± 6.5 0.31
LV ejection fraction (M-mode) 30.2 ± 5.6 32.3 ± 6.2 0.19
LV ejection fraction (2D Simpson) 32.1 ± 6.1 29.0 ± 7.4 0.15
Left atrial diameter (mm) 42.2 ± 6.4 49.0 ± 7.1 0.002
Mitral regurgitation (cm2) 5.2 ± 4.1 7.6 ± 3.5 0.009
Pulmonary artery systolic pressure (mm Hg) 35.4 ± 12.7 42.2 ± 16.4 0.10
Medications at randomization
Carvedilol (mg/day) 18.0 ± 13.6 12.8 ± 10.0 0.07
ACE inhibitors (% of target) 66.1%± 23.7% 74.0%± 25.5% 0.21
Values are means ± SD or n (%). ACE, angiotensin-converting enzyme; LV, left ventricular; MLWHF, Minnesota living with Heart Failure
questionnaire.
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0.53). Also, the average number of hospitalizations for HF
over the longer-term 13.5 months follow-up was lower in the
ivabradine group (1.0 ± 1.4) than control (2.1 ± 1.1, p=
0.003).
3.4. Effect of heart rate reduction on study outcomes
At the end of the 3 months’ follow-up, heart rate reduction sig-
niﬁcantly correlated with better exercise tolerance, quality of
life, LV ejection fraction, and NYHA class, and reduced num-
ber of hospitalizations (Fig. 2). Patients who achieved heart
rates <70 bpm at the end of study had a better NYHA class
(p= 0.002) and lower MLWHF questionnaire score (p=
0.044) than those with heart rates >80 bpm. Multivariate
analysis showed that heart rate reduction was a stronger pre-
dictor of better LV ejection fraction at the end of follow-up
(p= 0.024) than ivabradine treatment (p= 0.42).
4. Discussion
This study showed that adding ivabradine to the current guide-
line-based therapy in DCM patients with severe HF improved
different clinical and echocardiographic endpoints with asigniﬁcant correlation between lower heart rate and improved
echocardiographic and clinical outcomes.
Our patient population had characteristics of severe HF at
the time of randomization (Table 1). Notably, the patients in
the ivabradine group had a poorer clinical proﬁle than the pla-
cebo group with heightened sympathetic activity as shown by a
signiﬁcantly higher resting heart rate (96 versus 84 bpm). Mean
systolic blood pressure was lower than that in most trials of
beta-blockers in HF, for example, in US carvedilol in HF trial,
it was 115 ± 17 mm Hg and resting heart rate was 83 bpm.19
More than 50% of our population could not tolerate 50%
or more of the recommended target dose of 50 mg/day. By
contrast, 80% of patients in the US carvedilol in HF trial
achieved this dose.19 This is probably related to our more sick
patient population prior to randomization, where all of them
were in class III and IV HF. Also, we only included patients
with idiopathic DCM to have more homogeneous patient pop-
ulation and exclude underlying coronary artery disease of dif-
ferent severity that could bias our results.
The ivabradine group had lower resting heart rate than the
control group (73 versus 82 bpm). This is higher thanmean rest-
ing heart rates in some carvedilol trials, despite the higher mean
dose of carvedilol achieved in these trials.20 The exercise toler-
ance and quality of life signiﬁcantly improved with signiﬁcant
Figure 1 Changes in left ventricular end diastolic diameters (LVEDD, top left), end systolic diameter (LVESD, top right), end diastolic
volume (LVEDV, bottom left), and end systolic volume (LVESV, bottom right) at randomization (dark blue), and after 3 months’ follow-
up in the control group (pale blue) and the ivabradine group (red). *p value comparing the mean changes with ivabradine versus control. p
values for change over 3 months’ follow-up in the same group are shown above the bars on each histogram.
Table 2 Changes in heart rate, New York Heart Association (NYHA) class, exercise tolerance, quality of life, and left ventricular
(LV) ejection fraction.
Variable Change over follow-up
(mean ± SD)
p Value
Versus baseline Ivabradine versus control
Decrease in resting heart rate (bpm)
Ivabradine group 24.0 ± 13.0 <0.0001 <0.0001
Control group 3.0 ± 7.7 0.13
Improvement in NYHA class symptoms (%)
Ivabradine group 12 0.063 0.30
Control group 12 0.067
Increase in exercise tolerance (min)
Ivabradine group 3.7 ± 4.0 0.0021 0.03
Control group 1.2 ± 2.9 0.0029
Increase in quality of life (MLWHF score)
Ivabradine group 12.3 ± 3.3 0.0003 0.023
Control group 8.7 ± 5.2 0.0001
Increase in LV ejection fraction (%)
Ivabradine group 6.2 ± 8.3 0.0004 0.045
Control group 1.8 ± 6.7 0.22
MLWHF, Minnesota living with heart failure questionnaire.
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group in comparison to the control group. Carvedilol has been
shown to improve exercise tolerance in severeHFby 12%.21 Iva-
bradine as add-on therapy added a 39% increase in exercise tol-erance. Although the method of assessment was different from
other HF studies, it did allow for comparisons. In the trial of
Cohn et al., carvedilol did not improve the quality of life,22
but in other trials it did.20Many trials proved that beta-blockers
Figure 2 Correlations between changes in heart rate (HR) over the 3 months follow up period and exercise tolerance, left ventricular
ejection fraction (LVEF; M-mode), number of hospitalizations, and New York Heart Association (NYHA) class at the end of follow-up.
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further signiﬁcant improvement.
The ivabradine group had a statistically signiﬁcant increase
in LV ejection fraction (6.2%), and decreases in LV end systolic
diameter (3.9 mm), end systolic volume (16 mL), and end dia-
stolic volume (13 mL). These results are in agreement with those
of Berrie, who found a 5.3% increase in LV ejection fraction
with ivabradine and decreases in LV end systolic volume and
end diastolic volume of 18.5 and 8.2 mL, respectively.25
The heart rate reduction achieved at the end of 3 months’
follow-up was signiﬁcantly correlated with better exercise tol-
erance, quality of life, NYHA class, LV ejection fraction,
and decreased number of HF hospitalizations. Also, patients
achieving a resting heart rate <70 bpm had a better NYHA
class and better quality of life than patients with a resting heart
rate >80 bpm. These ﬁndings are in line with the meta-
analysis of beta-blocker HF trials that reported a strong corre-
lation between the magnitude of heart rate reduction and
improvement in LV ejection fraction,26 as well as improvement
in survival.23 Moreover, the BEAUTIFUL (morBidity-mortal-
ity EvAlUaTion of the If inhibitor ivabradine in patients with
coronary disease and left-ventricULar dysfunction) trial found
an 8% increase in death and 16% increase in HF hospitaliza-
tion for every 5-bpm increase in heart rate.27 At this point, it is
important to mention that the only subgroup of BEAUTIFUL
trial that demonstrated beneﬁts from ivabradine was that of
patients with a baseline heart rate greater than 70 bpm,17
which represents our entire study’s population (Table 1).The main limitations of our study are that it is a single cen-
ter trial and involved a small number of patients, and therefore
could not allow valid conclusions about mortality outcomes.
Other limitations are the lower dose of beta-blocker tolerated
in our patient population and the use of echocardiography for
the assessment of LV dimensions, volumes, and ejection
fraction, which is less reproducible than magnetic resonance
imaging or scintigraphy.
The conclusion of our study is that adding ivabradine to
optimal medical treatment in HF patients improves symptoms,
quality of life, effort tolerance, and echocardiographic
parameters, and reduces hospitalization. This beneﬁcial ivabr-
adine effect is probably due to its heart rate–reducing
properties.Competing interests
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